Quintet Private Bank Europe S.A. Sells 2,610 Shares of AbbVie Inc. $ABBV

Quintet Private Bank Europe S.A. cut its holdings in AbbVie Inc. (NYSE:ABBV) by 41.2% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,721 shares of the company’s stock after selling 2,610 shares during the period. Quintet Private Bank Europe S.A.’s holdings in AbbVie were worth $862,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in ABBV. Conning Inc. raised its stake in AbbVie by 7.1% during the second quarter. Conning Inc. now owns 191,023 shares of the company’s stock valued at $35,458,000 after purchasing an additional 12,690 shares in the last quarter. Dohj LLC increased its holdings in shares of AbbVie by 41.8% in the 2nd quarter. Dohj LLC now owns 4,529 shares of the company’s stock worth $802,000 after buying an additional 1,335 shares during the last quarter. First Hawaiian Bank raised its position in shares of AbbVie by 0.8% during the 2nd quarter. First Hawaiian Bank now owns 7,556 shares of the company’s stock valued at $1,403,000 after buying an additional 60 shares in the last quarter. BankPlus Trust Department lifted its holdings in shares of AbbVie by 3.3% in the 2nd quarter. BankPlus Trust Department now owns 27,113 shares of the company’s stock valued at $5,033,000 after acquiring an additional 855 shares during the last quarter. Finally, Whittier Trust Co. grew its position in AbbVie by 4.0% in the second quarter. Whittier Trust Co. now owns 237,030 shares of the company’s stock worth $43,997,000 after acquiring an additional 9,073 shares in the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

AbbVie Stock Up 0.3%

NYSE:ABBV opened at $224.32 on Thursday. The company has a market cap of $396.47 billion, a price-to-earnings ratio of 169.94, a price-to-earnings-growth ratio of 1.27 and a beta of 0.36. AbbVie Inc. has a twelve month low of $164.39 and a twelve month high of $244.81. The company has a current ratio of 0.72, a quick ratio of 0.60 and a debt-to-equity ratio of 44.14. The stock has a fifty day simple moving average of $226.87 and a 200-day simple moving average of $210.61.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The firm had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. During the same period in the prior year, the business posted $3.00 earnings per share. The business’s revenue for the quarter was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.1%. This is a boost from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date of this dividend is Friday, January 16th. AbbVie’s dividend payout ratio is 496.97%.

Analyst Ratings Changes

A number of brokerages have issued reports on ABBV. BMO Capital Markets upped their price objective on AbbVie from $215.00 to $240.00 and gave the company an “outperform” rating in a research report on Friday, September 12th. Scotiabank started coverage on AbbVie in a report on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 price target on the stock. UBS Group lifted their price objective on shares of AbbVie from $195.00 to $220.00 and gave the stock a “neutral” rating in a research note on Friday, November 7th. Erste Group Bank downgraded shares of AbbVie from a “buy” rating to a “hold” rating in a research note on Tuesday, October 14th. Finally, Bank of America lifted their price target on shares of AbbVie from $220.00 to $251.00 and gave the stock a “neutral” rating in a research note on Friday, October 3rd. Three research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $245.84.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.